Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The molecular target that AOD-9604 actually binds is still unidentified, which the FDA explicitly noted in its December 2024 evaluation
Symptoms of excessive intake are rare since your body will excrete any extra through your urine, adds Taylor
If travel involves heat, cold, or long delays, ask the dispensing pharmacist how to keep the product within the labeled storage range
This may be at room temperature [20-25C (68-77F)], refrigerated [2-8 C (36 -46 F)], or frozen [-15 to -25C (5 to -13F)]
The Rejuvapen device is then gently moved across the skin in a systematic pattern
04 Injection-site reaction Mild redness or swelling at the injection site is the most commonly reported AOD-9604 adverse event in trials
US$ 22.98
US$ 21.14
US$ 27.14
